U of MN researchers find genetic variations may predict treatment responses for myeloma

September 12, 2003

Researchers from The Cancer Center at the University of Minnesota have demonstrated that variations in genes may determine the outcome and toxicity of treatments for myeloma cancer patients. The findings support thinking that physicians may optimize care by adjusting treatment according to a patient's specific genetic condition. The findings will be presented September 15, 2003 at the American Association for Cancer Research (AACR)-sponsored specialty meeting on "SNPs, Haplotype, and Cancer: Application in Molecular Epidemiology."

Although chemotherapy drugs can be effective against myeloma in many patients, they can be less effective or even lethal in others. By determining a patient's toxic susceptibility to drugs through analysis of specific genetic variances, or single nucleotide polymorhphisms (SNPs), in genes known to promote myeloma growth, clinicians can adjust dosage levels or choose alternate, safer drugs to benefit the patient.

Led by Brian Van Ness, Ph.D., professor of genetics and a member of The Cancer Center, researchers analyzed patient samples from an Eastern Cooperative Oncology Group Study on myeloma chemotherapy treatments for 700 patients between 1987-1994. For this particular investigation, researchers examined 400 patient DNA samples for SNPs in genes that promote myeloma growth. Those patients with the SNPs that result in low production of the growth factor, generally had better outcomes to the chemotherapy and increased survival times.

"These data confirm that our research on genetic variances and their effect on treatment outcome is headed in the right direction," said Van Ness. "This important first step means we can start developing clinical trials based on genetic conditions that can lead to more effective treatments and help to evaluate new, targeted therapies."

Myeloma is a cancer of plasma cells, which are antibody-producing cells normally present in the bone marrow. More than 1,000 new cases or myeloma are diagnosed daily around the world making this the second most common form of blood cancer after lymphoma.
-end-
Co-authors of this study are William R. Kiffmeyer, Ph.D., Fangyi Zhao Ph.D. and Martin Oken M.D. of the University of Minnesota, and Emily Blood and Montse Rue, Ph.D. of the Easter Cooperative Oncology Group. The International Myeloma Foundation, through its Bank on a Cure project, will considerably expand this study in the future.

The Cancer Center at the University of Minnesota is a National Cancer Institute-designated Comprehensive Cancer Center. Awarded more than $80 million in peer-reviewed grants during fiscal year 2003, the Cancer Center conducts cancer research that advances knowledge and enhances care. The center also engages community outreach and public education efforts addressing cancer. To learn more about cancer, visit the University of Minnesota Cancer Center Web site at http://www.cancer.umn.edu. For cancer questions, call the Cancer Center information line at 1-888-CANCER MN (1-888-226-2376) or 612-624-2620 in the metro area.

Additional Contacts:
Todd Matthew
The Cancer Center (University of Minnesota)
612-624-6165

American Association for Cancer Research

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.